v3.26.1
Segment Reporting - Schedule of Segment Profit or Loss, Including Significant Segment Expenses (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Research and development expenses    
Total claseprubart program-related expenses $ 18,189 $ 16,591
Total research and development expenses 34,528 27,003
General and administrative expenses    
Total general and administrative expenses 12,468 7,337
Other income, net 5,699 3,666
Net Income (Loss) (40,834) (29,511)
License [Member]    
Revenues [Abstract]    
Revenues 463 1,163
Clinical operation activities [Member]    
Research and development expenses    
Total claseprubart program-related expenses 14,156 11,739
CMC activities [Member]    
Research and development expenses    
Total claseprubart program-related expenses 3,713 3,811
Preclinical study activity costs [Member]    
Research and development expenses    
Total claseprubart program-related expenses 320 1,041
Personnel and related costs [Member]    
Research and development expenses    
Total research and development expenses 8,635 5,847
General and administrative expenses    
Total general and administrative expenses 4,061 2,561
Stock-based compensation expense [Member]    
Research and development expenses    
Total research and development expenses 4,848 2,475
General and administrative expenses    
Total general and administrative expenses 5,754 2,840
Discovery expenses [Member]    
Research and development expenses    
Total research and development expenses 1,363 900
Other costs [Member]    
Research and development expenses    
Total research and development expenses 1,493 1,190
General and administrative expenses    
Total general and administrative expenses $ 2,653 $ 1,936